Chest Mobility, Strength, Physical Activity and Quality of Life in Parkinson's Patients With Post-COVID-19

NCT06008444 | Completed

• 1 other identifier: Effects of COVID on Parkinson
• Study Type: observational
• Target: 32
• Locations: 1 country
• Sites: 1

Brief Summary

To comparative pain intensity, chest mobility, cough strength, muscle strength, physical activity levels and quality of life in Parkinson's patients with post-COVID-19 and without post-COVID-19 was aimed in current study. Knowledge in the literature regarding this topic is still obscure.

Conditions

COVID-19 Respiratory Infection; Parkinson Disease

Keywords

pain; chest mobility; cough; muscle strength; physical activity; quality of life

Outcome Measures

Primary Outcomes (1)

• Total quality of life score evaluated by Parkinson's Disease Questionnaire (PDQ-39) questionnaire.

  The status of quality of life will be evaluated using Parkinson's Disease Questionnaire (PDQ-39) questionnaire. Parkinson's Disease Questionnaire-39 (PDQ39) is a 39-item quality of life questionnaire. Evaluation for each question item ranges from 0 (no problem) to 4 (constant problem). Low scores in total indicate an improvement in people's quality of life.

  through study completion, an average of 1 year

Secondary Outcomes (5)

• Cough Strength

  through study completion, an average of 1 year

• Daily average step count

  through study completion, an average of 1 year

• Hand grip strength

  through study completion, an average of 1 year

• Chest mobility

  through study completion, an average of 1 year

• Cognitive status

  through study completion, an average of 1 year

Study Arms (2)

Post-COVID-19 group

This group will consist of individuals with Parkinson disease who have had COVID-19.

Other: Physical Evaluations of post-COVID-19 individuals

Control group

The control group will consist of individuals with Parkinson disease without post-COVID-19.

Other: Physical Evaluations of non-post-COVID-19 individuals

Interventions

Physical Evaluations of post-COVID-19 individuals OTHER

In this research, the data of Parkinson's patients who have had COVID-19 will be collected face to face. Chest mobility, cough strength, muscle strength, physical activity and quality of life will be evaluated in all Parkinson's patients. The data to be obtained through all these evaluations will be collected from at one time and in a time lasting maximum of about 1 hour. Step count tracking with pedometer will be done for 3 days for each individual.

Post-COVID-19 group

Physical Evaluations of non-post-COVID-19 individuals OTHER

In this research, the data of Parkinson's patients who have not had COVID-19 will be collected face to face. Chest mobility, cough strength, muscle strength, physical activity and quality of life will be evaluated in all Parkinson's patients. The data to be obtained through all these evaluations will be collected from at one time and in a time lasting maximum of about 1 hour. Step count tracking with pedometer will be done for 3 days for each individual.

Control group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

At least 21 Parkinson's patients with post-COVID-19 will be included in the main group and at least 11 Parkinson's patients without post-COVID-19 will be included in control group.

You may qualify if:

• Being diagnosed with COVID-19 at least 12 weeks ago and recovered,
• Being over 18 years old,
• Volunteering to participate in the research,
• Being diagnosed with Parkinson's disease
• Comorbid conditions (such as hypertension, diabetes) are under control
• Being able to perceive assessments (Standardized Mini Mental Test score of 24 and above)
• Having the ability to ambulate and walk independently
• Being in stage 1 - 4 according to the Modified Hoehn-Yahr Scale
• Not being diagnosed or suspected of COVID-19
• Being over 18 years old,
• Volunteering to participate in the research,
• Being diagnosed with Parkinson's disease
• Having comorbid conditions (such as hypertension, diabetes) which are under control
• Being able to perceive assessments (Standardized Mini Mental Test score of 24 and above)
• Having the ability to ambulate and walk independently

You may not qualify if:

• Sudden drug or dose change during the study period
• A history of any acute/chronic orthopedic, cardiovascular, pulmonary, psychiatric or neuromuscular disease that may prevent measurements from being made.
• Having had myocardial infarction and pulmonary embolism in the last 30 days,
• Having a history of additional neurological (stroke, head trauma, peripheral nerve diseases, brain and spinal cord tumors, etc.) diseases other than Parkinson's disease
• Having severe vision loss or vestibular dysfunction
• Patients with blood pressure values above 140/90 and below 90/50 in blood pressure measurements made before the study, with arrhythmia on ECG, with a history of shortness of breath and/or palpitation

Sponsors & Collaborators

• Izmir Democracy University: lead

Study Sites (1)

Izmir Democracy University

Izmir, 35140, Turkey (Türkiye)

Location

Related Publications (2)

• Shalash A, Helmy A, Salama M, Gaber A, El-Belkimy M, Hamid E. A 6-month longitudinal study on worsening of Parkinson's disease during the COVID-19 pandemic. NPJ Parkinsons Dis. 2022 Aug 31;8(1):111. doi: 10.1038/s41531-022-00376-x.

  PMID: 36045133 BACKGROUND

• Shalash A, Roushdy T, Essam M, Fathy M, Dawood NL, Abushady EM, Elrassas H, Helmi A, Hamid E. Mental Health, Physical Activity, and Quality of Life in Parkinson's Disease During COVID-19 Pandemic. Mov Disord. 2020 Jul;35(7):1097-1099. doi: 10.1002/mds.28134. Epub 2020 Jun 7. No abstract available.

  PMID: 32428342 BACKGROUND

MeSH Terms

Conditions

Parkinson Disease; Pain; Cough; Motor Activity

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Respiration Disorders; Respiratory Tract Diseases; Signs and Symptoms, Respiratory; Behavior

Study Officials

• GÜLŞAH BARĞI

  Izmir Democracy University

  STUDY DIRECTOR

• MERVE ŞAHİN

  Izmir Democracy University

  PRINCIPAL INVESTIGATOR

• ÖZLEM ÇİNAR ÖZDEMİR

  Izmir Democracy University

  PRINCIPAL INVESTIGATOR

• YASEMİN ÜNAL

  Bandirma Health Practice and Research Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: August 21, 2023
• First Posted: August 23, 2023
• Study Start: May 13, 2023
• Primary Completion: August 30, 2024
• Study Completion: December 30, 2024
• Last Updated: May 18, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)